[O-methyl-11C]N-(4-(4-(3-Chloro-2-methoxyphenyl)-piperazin-1-yl)butyl)-1H-indole-2-carboxamide ([11C]BAK4-51) Is an Efflux Transporter Substrate and Ineffective for PET Imaging of Brain D3 Receptors in Rodents and Monkey

被引:2
作者
Liow, Jeih-San [1 ]
Morse, Cheryl L. [1 ]
Lu, Shuiyu [1 ]
Frankland, Michael [1 ]
Tye, George L. [1 ]
Zoghbi, Sami S. [1 ]
Gladding, Robert L. [1 ]
Shaik, Anver B. [2 ]
Innis, Robert B. [1 ]
Newman, Amy H. [2 ]
Pike, Victor W. [1 ]
机构
[1] NIMH, Mol Imaging Branch, NIH, Room B3C346,10 Ctr Dr, Bethesda, MD 20892 USA
[2] NIDA, Med Chem Sect, Mol Targets & Medicat Discovery Branch, NIH, 333 Cassell Dr, Baltimore, MD 21224 USA
基金
美国国家卫生研究院;
关键词
dopamine D-3 receptors; antagonist; radiolabeling; PET; efflux transporter substrate; POSITRON-EMISSION-TOMOGRAPHY; DOPAMINE D3 RECEPTOR; POTENTIAL RADIOTRACER; IN-VIVO; DRUG DISCOVERY; FREE-FRACTION; D2; RECEPTORS; BINDING; ANTAGONISTS; AFFINITY;
D O I
10.3390/molecules23112737
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Selective high-affinity antagonists for the dopamine D-3 receptor (D3R) are sought for treating substance use disorders. Positron emission tomography (PET) with an effective D3R radioligand could be a useful tool for the development of such therapeutics by elucidating pharmacological specificity and target engagement in vivo. Currently, a D3R-selective radioligand does not exist. The D3R ligand, N-(4-(4-(3-chloro-2-methoxyphenyl)piperazin-1-yl)butyl)-1H-indole-2-carboxamide (BAK4-51, 1), has attractive properties for PET radioligand development, including full antagonist activity, very high D3R affinity, D3R selectivity, and moderate lipophilicity. We labeled 1 with the positron-emitter carbon-11 (t(1/2) = 20.4 min) in the methoxy group for evaluation as a radioligand in animals with PET. However, [C-11]1 was found to be an avid substrate for brain efflux transporters and lacked D3R-specific signal in rodent and monkey brain in vivo.
引用
收藏
页数:14
相关论文
共 56 条
[1]   Molecular imaging with PET [J].
Ametamey, Simon M. ;
Honer, Michael ;
Schubiger, Pius August .
CHEMICAL REVIEWS, 2008, 108 (05) :1501-1516
[2]   High Affinity Dopamine D3 Receptor (D3R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D3R Knockout Mice [J].
Boateng, Comfort A. ;
Bakare, Oluyomi M. ;
Zhan, Jia ;
Banala, Ashwini K. ;
Burzynski, Caitlin ;
Pommier, Elie ;
Keck, Thomas M. ;
Donthamsetti, Prashant ;
Javitch, Jonathan A. ;
Rais, Rana ;
Slusher, Barbara S. ;
Xi, Zheng-Xiong ;
Newman, Amy Hauck .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (15) :6195-6213
[3]  
Boy C, 1998, SYNAPSE, V30, P341
[4]   Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist [J].
Chien, Ellen Y. T. ;
Liu, Wei ;
Zhao, Qiang ;
Katritch, Vsevolod ;
Han, Gye Won ;
Hanson, Michael A. ;
Shi, Lei ;
Newman, Amy Hauck ;
Javitch, Jonathan A. ;
Cherezov, Vadim ;
Stevens, Raymond C. .
SCIENCE, 2010, 330 (6007) :1091-1095
[5]  
DAMHAUT P, 1992, APPL RADIAT ISOTOPES, V43, P1265
[6]   [11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein [J].
Froklage, Femke E. ;
Syvanen, Stina ;
Hendrikse, N. Harry ;
Huisman, Marc C. ;
Molthoff, Carla Fm ;
Tagawa, Yoshihiko ;
Reijneveld, Jaap C. ;
Heimans, Jan J. ;
Lammertsma, Adriaan A. ;
Eriksson, Jonas ;
De lange, Elizabeth C. M. ;
Voskuyl, Rob A. .
EJNMMI RESEARCH, 2012, 2
[7]   Affinity and selectivity of [11C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo [J].
Gallezot, Jean-Dominique ;
Beaver, John D. ;
Gunn, Roger N. ;
Nabulsi, Nabeel ;
Weinzimmer, David ;
Singhal, Tarun ;
Slifstein, Mark ;
Fowles, Krista ;
Ding, Yu-Shin ;
Huang, Yiyun ;
Laruelle, Marc ;
Carson, Richard E. ;
Rabiner, Eugenii A. .
SYNAPSE, 2012, 66 (06) :489-500
[8]   EVALUATION OF ULTRAFILTRATION FOR THE FREE-FRACTION DETERMINATION OF SINGLE-PHOTON EMISSION COMPUTED-TOMOGRAPHY (SPECT) RADIOTRACERS - BETA-CIT, IBF, AND IOMAZENIL [J].
GANDELMAN, MS ;
BALDWIN, RM ;
ZOGHBI, SS ;
ZEAPONCE, Y ;
INNIS, RB .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (07) :1014-1019
[9]   The role of molecular imaging in drug discovery and development [J].
Hargreaves, R. J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :349-353
[10]   Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders [J].
Heidbreder, Christian A. ;
Newman, Amy H. .
ADDICTION REVIEWS 2, 2010, 1187 :4-34